• UPDATE : 2019.10.16 수 16:44
상단여백
기사 (전체 76건)
Takeda Reports 1st Quarter FY2017 Results…Strong start to FY2017 with double-digit EPS growth; confirms confidence in full-year outlook
Takeda Pharmaceutical Company Limited (TOKYO:4502):Underlying Revenue growt...
라인
Janssen Receives Positive CHMP Opinion for SYMTUZA The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
Janssen-Cilag International NV (Janssen) today announced that the Committee...
라인
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS(brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phas...
라인
ATS 2017 Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status
Boehringer Ingelheim today announced new analyses that provide further evidence that adding tiotropium Respimat® (Sp...
라인
Takeda Reports FY2016 Full Year Results and Issues FY2017 Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502):Delivered substantial profit growth versus prior year· Underlying Rev...
라인
US FDA Expands Approval of Tiotropium Respimat for Maintenance Treatment of Asthma in Children
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (mar...
라인
Takeda Recognized as One of the Global 100 Most Sustainable Corporations for Second Consecutive Year
Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights to the 2017 Glo...
라인
AstraZeneca Presents Tagrisso Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases
AstraZeneca reported further evidence that Tagrisso (osimertinib), the pote...
라인
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (N...
라인
Takeda and Zydus Cadila partner to address the global threat of Chikungunya
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Zydus Cadila today announced a partnership to tackle c...
라인
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind usage in clinical practice
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice Praxbind® ...
라인
Takeda Receives Marketing Authorization in Canada for NINLARO in Relapsed·Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada ...
라인
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin...
라인
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
INGELHEIM, GERMANY & DUNDEE, SCOTLAND--(Business Wire/Korea Newswire) July 15, 2016 -- Scotland--(BUSINESS WIRE)-- Boehr...
라인
ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS
LONDON--AstraZeneca and MedImmune, its global biologics research and development arm, today announced publication in The...
라인
Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
Takeda Pharmaceutical Company Ltd. (TOKYO:4502) (http://goo.gl/eX9kbP) and enGene, Inc. today announced a strategic alli...
Back to Top